TetraLogic nabs $32M round for lead cancer therapy

Malvern, PA-based TetraLogic Pharmaceuticals has rounded up $32 million in Series C cash to back the development of its lead cancer drug, the early-stage TL32711. Clarus Ventures led the round with new investor Hatteras Venture Partners joining Amgen Ventures, HealthCare Ventures, Latterell Venture Partners, Novitas Capital, Quaker BioVentures and the Vertical Group in the venture round. TL32711 is a SMAC mimetic designed to neutralize the activity of an inhibitor of apoptosis proteins, which...